Clinical / Therapeutics / Therapies / Biotech / Cancer / BioTech / National blog main / San Francisco / San Francisco blog main / San Francisco top stories / Acorn Pacific / cancer / CAR-T / Cell Therapy / Cheng Liu / Eureka Therapeutics / Financing / Life Sciences / Lyell Immunopharma / Rick Klausner / solid tumor / TCR / VC / Venture Capital

Eureka Partners With Lyell to Tackle Tricky Solid Tumor Cell Therapies

Posted On: Mar 20, 2020   |   Posted By: Xconomy

Eureka Partners With Lyell to Tackle Tricky Solid Tumor Cell Therapies

Eureka Therapeutics, which has been developing methods to facilitate the development of cell therapies that can treat solid cancers, has raised $45 million to prove out its technologies in the clinic. To enhance its chances of success, the Emeryville, CA-based company has struck an agreement to work with Lyell Immunopharma, another San Francisco Bay Area biotech. Lyell, which is also working on developing on T-cell therapies to treat cancerous tumors, led Eureka's new funding round, a Series E financing. Cell therapies use a patients' own living T cells, reengineered to better fight cancer. Two CAR-T cell therapies have been approved for...

Continue reading ...